<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Quantifying Importance MSP1-19 Target of <br /> Growth-Inhibitory Protective Antibodies against <br /> Plasmodium falciparum Humans <br /> Danny W. Wilson1,2, Freya J. I. Fowkes1,3, Paul R. Gilson3,4, Salenna R. Elliott1,3, Livingstone Tavul5, <br /> Pascal Michon5,6, Elija Dabod5, Peter M. Siba5, Ivo Mueller1,5,7, Brendan S. Crabb2,3, James G. Beeson1,3* <br /> 1 The Walter Eliza Hall Institute Medical Research, Parkville, Australia, 2 University Melbourne, Melbourne, Australia, 3 Macfarlane Burnet Institute Medical <br /> Research Public Health, Melbourne, Australia, 4 Monash University, Clayton, Australia, 5 Papua New Guinea Institute Medical Research (PNGIMR), Goroka, Papua <br /> New Guinea, 6 Faculty Health Sciences, Divine Word University, Madang, Papua New Guinea, 7 Barcelona Centre International Health Research (CRESIB), Barcelona, <br /> Spain <br />  <br />  <br />  <br />      <span id='am-1' about='protege:abstract' typeof='owl:Thing'>Abstract</span> <br />      Background: Antibodies targeting blood stage antigens important protection malaria, key targets and <br />      mechanisms immunity understood. Merozoite surface protein 1 (MSP1) abundant essential protein. <br />      The C-terminal 19 kDa region (MSP1-19) regarded promising vaccine candidate important target <br />      immunity. <br />  <br />      Methodology/Findings: Growth inhibitory antibodies asexual-stage parasites IgG recombinant MSP1-19 <br />      measured plasma samples longitudinal cohort 206 children Papua New Guinea. Differential inhibition by <br />      samples mutant P. falciparum lines expressed P. falciparum P. chabaudi form MSP1-19 used <span id='am-3' about='protege:TO' typeof='owl:Thing'>to</span> <br />      quantify MSP1-19 specific growth-inhibitory antibodies. The great majority children detectable IgG MSP1-19, and <br />      high levels IgG significantly associated reduced risk symptomatic P. falciparum malaria 6-month <br />      follow-up period. However, little evidence PfMSP1-19 specific growth inhibition plasma samples <span id='am-2' about='protege:FROM' typeof='owl:Thing'>from</span> <br />      children. Similar results testing non-dialysed dialysed plasma, purified antibodies, when <br />      measuring growth inhibition flow cytometry microscopy-based assays. Rabbit antisera generated immunization <br />      recombinant MSP1-19 demonstrated strong MSP1-19 specific growth-inhibitory activity, appeared to <br />      higher antibody levels human samples; antibody avidity similar rabbit antisera human plasma. <br />  <br />      Conclusions/Significance: These data suggest MSP1-19 major target growth inhibitory antibodies that <br />      protective effects antibodies MSP1-19 growth inhibitory activity, instead mediated by <br />      mechanisms. Alternatively, antibodies MSP1-19 act marker protective immunity. <br />  <br />   Citation: Wilson DW, Fowkes FJI, Gilson PR, Elliott SR, Tavul L, et al. (2011) Quantifying Importance MSP1-19 Target Growth-Inhibitory Protective <br />   Antibodies Plasmodium falciparum Humans. PLoS ONE 6(11): e27705. doi:10.1371/journal.pone.0027705 <br />   Editor: Georges Snounou, Universite&#194;&#180; Pierre et Marie Curie, France <br />   Received June 29, 2011; Accepted October 23, 2011; Published November 15, 2011 <br />   Copyright: &#195;&#376; 2011 Wilson et al. This open-access article distributed terms Creative Commons Attribution License, permits <br />   unrestricted use, distribution, reproduction medium, provided original author source credited. <br />   Funding: Funding provided National Health Medical Research Council Australia (project grant career development award JB; training <br />   award FF, postgraduate research fellowship DW; Infrastructure Research Institutes Support Scheme Grant), Australian Research Council (Future <br />   Fellowship JB), Victorian State Government Operational Infrastructure Support grant. The funders role study design, data collection and <br />   analysis, decision publish, preparation manuscript. <br />   Competing Interests: The authors declared competing interests exist. <br />   * E-mail: beeson@burnet.edu.au <br />  <br />  <br />  <br /> Introduction                                                                            effective immunity malaria develops repeated <br />                                                                                         exposure limits blood-stage parasitemia prevents <br />    Between 300&#226;&#8364;&#8220;500 million cases clinical malaria occur                         symptomatic illness severe complications [6]. Antibodies to <br /> year resulting approximately 1 million deaths,                             merozoite proteins appear important component of <br /> children 5 years age sub Saharan Africa [1&#226;&#8364;&#8220;3]. The                          acquired immunity humans high levels IgG number <br /> major causative agent malaria mortality Plasmodium falciparum.                    surface proteins invasion ligands associated with <br /> Although disease burden P. falciparum considered fall                      protection malaria [7&#226;&#8364;&#8220;22]. Antibodies merozoite proteins <br /> mainly Africa, 25% thought occur Asia [4].                           thought act direct inhibition invasion, through <br />    Malaria disease occurs blood-stage infection                             antibody-dependent cell-mediated immune mechanisms [23,24]. <br /> merozoites invade human red blood cells (RBCs) replicate                            However, antibody effector mechanisms specific targets of <br /> inside them. Invasion RBCs complex process involving                        functional antibodies poorly understood. <br /> interaction proteins present surface apical                           Merozoite surface protein 1 (MSP1), ,200 kDa GPI <br /> organelles merozoite receptors RBC surface                           anchored merozoite surface protein consisting 17 blocks of <br /> (reviewed Gaur et al. 2004 [5]). In malaria-endemic areas                            conserved variable regions [25,26]. MSP1 abundant the <br />  <br />  <br />         PLoS ONE | www.plosone.org                                                  1                           November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                                 Antibodies Immunity Malaria <br />  <br />  <br /> merozoite surface efforts <span id='am-4' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-5' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-8' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-9' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-11' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-12' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-13' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-15' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-20' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-23' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-25' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-26' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-34' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-35' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-36' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-37' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-39' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-45' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-47' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-51' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-54' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-57' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-60' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-66' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-69' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-71' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span>knock-out</span> protein              antibodies antibodies generated experimental animals by <br /> unsuccessful, suggesting MSP1 essential parasite                  vaccination recombinant protein. <br /> invasion and/or growth [27,28]. MSP1 proteolytically processed <br /> into 83-, 30-, 38-kDa, C-terminal 42-kDa (MSP1-42)                        Materials Methods <br /> fragments just egress schizont. These shed, <br /> leaving C-terminal fragment runs 19 kDa                 Study participants design <br /> non-reducing gel (termed MSP1-19) parasite membrane                       Samples collected pediatric treatment-reinfection <br /> post invasion [29&#226;&#8364;&#8220;35]. The function MSP1 remains unclear,              study undertaken June December 2004 Mugil <br /> MSP1-19 reported bind RBC protein Band 3 [36],                Elementary School (n = 152), Megiar Elementary School (n = 44) <br /> and recent studies suggest MSP1-42 interacts heparin-like                Megiar Primary School (n = 10), 50 km North Madang, <br /> molecules RBC [37].                                                    Madang Province, Papua New Guinea [62]. The study was <br />    A number studies shown high levels MSP1-19                 approved Medical Research Advisory Committee (MRAC), <br /> IgG antibodies measured ELISA associated protection               Papua New Guinea Ministry Health, The Walter Eliza Hall <br /> from P. falciparum malaria [20,38&#226;&#8364;&#8220;43]. Affinity purified MSP1-19              Institute Human Research Ethics Committee institutional <br /> specific human antibodies MSP1-19 domain II [44]                 review board Veteran&#226;&#8364;&#8482;s Affairs Medical Center (Cleveland, <br /> (10&#226;&#8364;&#8220;100 fold higher initial serum concentration),                Ohio). Written consent obtained parents/guardians of <br /> domain I [45], MSP1-19 reported inhibit merozoite                  participants. A total 206 children aged 5 14 enrolled <br /> invasion vitro. Vaccination using recombinant MSP1-19 antigens             (median 9.3 years; interquartile range 8.1 10.3 years). <br /> and passive transfer MSP1-19 antibodies reported                  Enrolment peripheral blood data collection was <br /> confer protection malaria disease mouse monkey               conducted two-week period June 2004 staff from <br /> models malaria [46&#226;&#8364;&#8220;50].                                                    PNGIMR [62]. After physical examination baseline bleed, the <br />    Several mechanisms MSP1-19 antibodies                         children treated 7 day course artesunate, according <br /> mediate protection malaria suggested vaccine                national guidelines, clear current malarial infections. <br /> studies. These include antibody binding 19 kDa fragment                Over 6 months, malaria parasitemic episodes were <br /> and inhibiting protein function merozoite invasion                     identified fortnightly follow-ups (active surveillance) and <br /> erythrocytes, disruption secondary processing MSP1                  review trained health worker child enrolled the <br /> precursor, agglutination merozoites opsonising parasites           study presented symptoms local Mugil Health <br /> destruction phagocytic cells [31,34,51&#226;&#8364;&#8220;53].                                Centre (passive surveillance). In cases symptoms indicated a <br />    Efforts study role function naturally acquired               current recent fever, blood smears prepared <br /> PfMSP1-19 antibodies protection P. falciparum disease            screen parasite infection estimation parasitemia. <br /> facilitated development MSP1-19 transgenic parasites.               Children diagnosed malaria treated sulfadoxine/ <br /> The 19 kDa fragment P. falciparum isolate D10 (MAD-20 allele)              pyrimethamine amodiaquine cover P. falciparum P. vivax <br /> was replaced 19 kDa region rodent malaria P.                  according national guidelines. <br /> chabaudi (PcMEGF) [54] endogenous D10 MSP1-19                        Data relating time reinfection treatment, infecting <br /> sequence (PfM39) [27] act wild-type control. Growth            malaria parasite species indicated PCR, parasite density as <br /> PcMEGF PfM39 lines inhibited polyclonal                indicated microscopy, red blood cell polymorphisms PCR, <br /> antibodies raised recombinant antigens,                   history illness indicated symptoms physical <br /> evidence significant cross inhibitory activity antigens.           examination available [62,63]. Some samples also <br /> This approach provided tools measure growth inhibitory                     collected PNG adults region, residents <br /> antibodies vitro specific MSP1-19 [54].                        Melbourne, Australia, act non-malaria-exposed controls. <br />    Several studies using transgenic parasites reported <br /> that PfMSP1-19 specific antibodies large component               Measurement PfMSP1-19 specific antibodies ELISA <br /> total vitro growth inhibitory activity untreated serum                 DNA sequences P. falciparum MSP1-19 P. chabaudi <br /> plasma malaria-exposed individuals [54&#226;&#8364;&#8220;60]. In study                 MSP1-19 ligated modified pMal-C2x plasmid (New <br /> people high levels PfMSP1-19 specific inhibitory activity          England Biolabs) produce MSP1-19 fusions proteins N- <br /> their plasma likely reinfected P. falciparum       terminal Maltose Binding Protein (MBP) tag. The fusion proteins <br /> drug treatment [55]. However, studies using PcMEGF,                 expressed Escherichia coli BL21(DE3) Origami (Novagen, <br /> or similar transfectant using P. yoelii MSP1-19 (PyMEGF),                   Madison, WI, U.S.A.) purified nickel-nitrilotriacetic acid <br /> showed association PfMSP1-19 specific growth                       chromatography native conditions (Qiagen, Valencia, CA, <br /> inhibitory activity infection status [58,59]. Interestingly,              U.S.A.) refolded Dutta et al. [64]. Correct folding <br /> several studies level PfMSP1-19 specific growth             PfMSP1-19 fusion protein verified western blot <br /> inhibition correlated poorly levels PfMSP1-19 antibodies              analysis reduction sensitive monoclonal antibody 4H9/19 <br /> measured ELISA [54&#226;&#8364;&#8220;56,59,61]. Importantly, study                [65]. <br /> examined association MSP1-19 inhibitory antibodies                   Antigens coated ELISA plates (Costar, Cambridge, <br /> and prospective risk symptomatic malaria.                                  MA, U.S.A.) 1 mg/ml 100 ml PBS incubated overnight at <br />    In study, functional antibodies MSP1-19                    4uC [21,22,66]. Plates washed 3 times PBS 0.05% <br /> importance MSP1-19 target acquired immunity                   Tween-20 (0.05% PBS-T, Sigma Aldrich, St Louis, MO, U.S.A.) <br /> evaluated. The contribution MSP1-19 specific antibodies             room temperature (RT) blocked 200 ml 10% skim milk <br /> total invasion-inhibitory activity acquired antibodies                 0.05% PBS-T 2 hours 37uC. The plates washed 3 <br /> quantified, associations antibodies MSP1-19                times 0.05% PBS-T heat inactivated plasma samples <br /> protection parasitization, high grade parasitemia,                   (100 ml volume diluted 1/500 PBS 0.05% sodium azide) <br /> malarial illness examined pediatric treatment-reinfection           added incubated RT 2 hours. Plates washed <br /> study Papua New Guinea (PNG). Furthermore, differences                  3 times 0.05% PBS-T 100 ml HRPO-conjugated Sheep <br /> functional activity evaluated acquired human                       anti human IgG (Millipore, Boronia, Melbourne, Australia) <br />  <br />  <br />        PLoS ONE | www.plosone.org                                         2                      November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                             Antibodies Immunity Malaria <br />  <br />  <br /> diluted 1:2500 0.05% PBS-T 5% milk added                      non-exposed Melbourne donors purified using ammonium <br /> incubated RT 1 hour. The plates washed 3 times             sulfate precipitation [67,68]. Briefly, 300 ml plasma diluted <br /> 0.05% PBS-T 100 ml ABTS substrate (Sigma Aldrich, St               1:5 normal saline. Saturated ammonium sulfate (Sigma Aldrich, <br /> Louis, MO, U.S.A.) incubated 15 minutes           St Louis, MO, U.S.A., approximately 1 kg/L water, auto- <br /> RT. The reaction stopped addition 100 ml 1%            claved) added drop wise make 40% total volume <br /> SDS read 405 nm (Tecan Genios, Gro&#194;&#168;dig, Austria). A                incubated ice 30 minutes. The solution spun <br /> panel samples malaria-exposed adults acted positive            13000(G) 15 minutes 4uC removal the <br /> controls enable comparison antibody levels plates           supernatant. The pellet washed 50% ammonium sulfate <br /> and different dates experiments. A panel serum                 solution water pelleting removal supernatant a <br /> Melbourne donors acted negative controls.                              second time. The pellet resuspended 400 ml RPMI- <br />    PfMSP1-19 specific IgG concentration estimated coating          HEPES resulting solution dialysed according the <br /> two-fold serial dilutions (1 mg/ml-0.00781 mg/ml) purified             preceding method. Immunoglobulin resuspended spin <br /> human IgG (reagent grade; Sigma-Aldrich, St. Louis MO,                    column half original sample volume concentrate the <br /> U.S.A) purified rabbit IgG (reagent grade; Sigma-Aldrich,             sample approximately twice initial immunoglobulin <br /> St. Louis MO, U.S.A) plates; wells coated            concentration. <br /> recombinant PfMSP1-19. After blocking wells 10% skim <br /> milk, two-fold serial dilutions Mugil children&#226;&#8364;&#8482;s plasma (1/1000&#226;&#8364;&#8220;       PfMSP1-19 specific growth inhibition assays <br /> 1/32000) rabbit sera MSP1-19 (1/4000&#226;&#8364;&#8220;1/256000)                    The PcMEGF (containing PcMSP1-19) PfM39 (containing <br /> were added separate wells coated 1 mg/ml PfMSP1-19.               PfMSP1-19) lines [27,54] PcPHG PfPHG GFP <br /> PBS added wells coated human rabbit IgG. After            fluorescent MSP1-19 transfected lines [69] used study <br /> incubation 2 hours, wells washed, incubated            referred simply PcMSP1-19 line PfMSP1-19 <br /> either anti-human anti-rabbit IgG secondary antibody,             line; transgenic parasites generated isolate D10 (derived <br /> washed processed described above. The MSP1-19 specific             PNG isolate FC27). The expression PcMSP1-19 <br /> IgG concentration children&#226;&#8364;&#8482;s plasma, rabbit antisera,            PfMSP1-19 alleles transfected parasite lines was <br /> was estimated reference standard curve human              confirmed Western blot immunofluorescence assays as <br /> rabbit IgG, respectively. Estimated MSP1-19 specific IgG levels           described O&#226;&#8364;&#8482;Donnell et al. 2000 [27]. Parasites cultured as <br /> among human samples expressed relative rabbit                 described [69,70]. PfMSP1-19 PcMSP1-19 transfected lines <br /> MSP1-19 anti-sera.                                                        maintained 24 ng/ml pyrimethamine (to select MSP1- <br />                                                                           19 transfectants, Sigma Aldrich, St Louis, MO, U.S.A.) 5 mg/ <br /> Estimating antibody avidity ELISA                                      ml blasticidin-S-HCl (to select GFP transfectants, Invitrogen, <br />    After incubating antigen-coated wells human plasma             Carlsbad, CA, U.S.A.) added culturing double <br /> rabbit anti-MSP1-19 antibodies (as described above), wells           transfected fluorescent lines. One cycles prior assay <br /> washed incubated ammonium thiocyanate (Sigma-               setup, assay, drugs excluded cultures. <br /> Aldrich, St. Louis MO, U.S.A) 20 minutes concentrations            The protocol measurement antibody inhibition parasite <br /> 8.64 M, 6.91 M, 5.18 M, 4.32 M, 3.46 M, 2.16 M, 1.728 M,                  growth used study modified Persson et al. [67] is <br /> 1.08 M, 0.27 M, 0.135 M, 0.067 M. Wells washed              described validated [69]. Parasites were <br /> the assay completed described earlier. Primary antibodies          cultured cycles asexual replication. Mid late <br /> were diluted human (1/2000, 1/4000) rabbit (1/20000, 1/           trophozoite stage cultures (30&#226;&#8364;&#8220;40 hours) washed fresh <br /> 40000) samples yield OD values descending linear section        culture medium (37uC) pelleted centrifugation diluted <br /> of absorbance curves. The ammonium thiocyanate concen-                0.5% 1% parasitemia 1% hematocrit 1 cycle <br /> tration resulted loss 50% maximum absorbance          assay 0.1% 0.3% parasitemia 1% hematocrit 2 cycle <br /> estimated fitting line best fit.                                  assay. Fresh culture medium fresh RBCs 2 different <br />                                                                           donors warmed 37uC used assay set-up. Parasitised <br />                                                                           RBCs appropriate parasitemia, volume 25 ml or <br /> Sample dialysis <br />                                                                           50 ml, added 96 U-bottom plate (Falcon, Becton- <br />    Heat inactivated plasma samples (45 minutes 56uC) were <br />                                                                           Dickinson, Franklin Lakes, NJ, U.S.A) 2.5 ml 5 ml of <br /> dialysed described [67,68]. Briefly, 200 ml sample added <br />                                                                           sample (for 25 ml 50 ml assays respectively) added 1 in <br /> to 50 kDa cut-off Tube-O-Dialyzer dialysis tubes (Chemicon <br />                                                                           10 dilution sample. All samples run duplicate in <br /> International, Temecula, CA, U.S.A) tubes placed             cases repeat experiments. A panel non-immune serum <br /> upside PBS dialysis membrane contacted PBS.            Melbourne donors (provided Australian Red Cross) <br /> Samples left dialyse 2 hours 4uC PBS          included non-inhibitory controls. The 96 plates were <br /> was replaced dialysis overnight. Samples                 placed humidified air tight culture box left 37uC 1% <br /> centrifuged the dialysis tubes transferred        O2, 4% CO2 95% N2. <br /> 100 kDa cut-off Nanosep spin tubes (Pall Life Sciences, Ann                  One cycle assays measurement parasitemia ring-stage <br /> Arbor, MI, U.S.A.) centrifuged 13000(G) 30 minutes          microscopy flow cytometry cultured approxi- <br /> 4uC. Sterile PBS (200 ml) added spin tube centrifuged         mately 24 hours young mid rings present no <br /> at 13000(G) 4uC. PBS added bring samples            schizont stage parasites remained. For assessment parasitemia <br /> the original sample volume (200 ml) stored 270uC.                  microscopy, smears cell pellets methanol fixed <br />                                                                           stained 5% Giemsa (Merck, Darmstadt, Germany). <br /> Purification immunoglobulins ammonium sulfate                       Slides blinded thousand RBCs counted for <br /> precipitation                                                             slide. Only early late rings (0 20 hours old) counted <br />    Immunoglobulin pooled Mugil samples high              parasitised RBCs, infected RBC counted single <br /> levels PfMSP1-19 specific antibody measured ELISA                   parasitized RBC regardless parasites cell. <br /> (OD.1.7), 5 plasma samples PNG adults serum                 Due variability inherent microscopy based counts of <br />  <br />  <br />       PLoS ONE | www.plosone.org                                      3                      November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                               Antibodies Immunity Malaria <br />  <br />  <br /> parasitemia [67,69], parasitemia counts duplicate wells             test. Spearman&#226;&#8364;&#8482;s correlation used determine correlations <br /> were reviewed second person duplicate wells                   data sets. These tests performed Prism 5.0a <br /> differed .25% slides recounted blinded. Where           (GraphPad Software Inc, San Diego, CA, U.S.A.). To determine <br /> slides recounted, counts used calculate               association antibody levels risk P. falciparum <br /> parasitemia.                                                                infection symptomatic malaria, ELISA data stratified <br />    One cycle assays measurement parasitemia                  3 equal groups (tertiles) reflecting low, medium high <br /> pigmented trophozoite stage cultured 48 hours post set-            responders according OD values antigen. GIA data <br /> up parasites 30&#226;&#8364;&#8220;40 hours post invasion              categorised (#0%, ,5%, 5&#226;&#8364;&#8220;9.99% $10% <br /> they prepared flow cytometric analysis appropriate.             inhibition). Kaplan-Meier curves generated time-to-event <br /> Two cycle trophozoite stage assays supplemented 48 hours            (infection clinical episode) data compared using log-rank <br /> post set-up (parasites 30&#226;&#8364;&#8220;40 hours post invasion) addition         test. Cox proportional hazards models used calculate <br /> of 5 ml 10 ml (25 ml 50 ml assay respectively) fresh culture       hazard ratios association antibody variables risk of <br /> medium warmed 37uC. Forty-eight (1 cycle assay) 96 (2 cycle           high density P. falciparum parasitemia symptomatic P. falciparum <br /> assay) hours post assay set-up, trophozoite stage assays               malaria. Assumptions proportional hazards assessed <br /> prepared flow cytometry analysis appropriate. For non-               graphically antibody variables showed non-propor- <br /> fluorescent parasite lines, RBCs resuspended 100 ml              tional hazards, results Cox regression including antibody <br /> PBS 10 mg/ml ethidium bromide (EtBr, Bio-Rad, Hercules,                variable antibody variable time interaction reported <br /> CA U.S.A.), stained 1 hour centrifugation, removal          [21,22]. Hazard ratios reported unadjusted adjusted the <br /> of supernatant resuspension 200 ml PBS. GFP                   predefined covariates age (binary variable: ,9 years, $9 years) <br /> fluorescent parasite lines resuspended PBS make final          location residence [21,22,62]. Data analysis performed <br /> volume 200 ml. Parasitemia measured Becton                      using STATA 9.2 statistical analysis software (STATA Corpora- <br /> Dickinson FACSCalibur (Franklin Lakes, NJ, U.S.A) flow                      tion, College Station, TX, U.S.A.). <br /> cytometer 96 plate sampler attached using Fl-2 <br /> (excitation wavelength 488 nm) EtBr stained parasites Fl-1          Results <br /> (excitation wavelength 488 nm) GFP parasites. Typically, <br /> 50,000 80,000 RBCs counted well. Samples              Acquisition P. falciparum MSP1-19 specific antibodies <br /> analysed using FlowJo software (Tree Star Inc, Ashland, OR,                 plasma ELISA <br /> U.S.A).                                                                        Previously described presence antibodies to <br />    PfMSP1-19 growth inhibitory activity measured assay              recombinant PfMSP1-19 (his-tagged, expressed E. coli) this <br /> may include invasion inhibition intraerythrocytic                  cohort [43]. In present study, antibodies recombinant <br /> parasite growth inhibition. Although PfMSP1-19 specific inhibi-             MSP1-19 P. falciparum P. chabaudi measured. <br /> tory antibodies acting mecha-               Comparison IgG levels PcMSP1-19 PfMSP1- <br /> nisms, mechanisms differentiated study. For         19 antigens allowed measurement antibodies specific to <br /> both PcMSP1-19 PfMSP1-19 transfected lines, parasite                PfMSP1-19, accounting cross-reactive non-specific antibod- <br /> growth (G) determined dividing mean parasitemia               ies. PfMSP1-19 specific antibodies calculated deducting <br /> duplicate wells test sample (Smean) mean parasitemia        reactivity PcMSP1-19 reactivity PfMSP1-19 for <br /> 2 wells non-inhibitory control (Cmean, typically                 sample. Quantifying relative levels antibodies P. <br /> Melbourne control serum) multiplying 100 (G = {Smean/                falciparum P. chabaudi MSP1-19 important interpret <br /> Cmea}*100). PfMSP1-19 specific inhibitory activity (InhPf)            results growth inhibition assays using MSP1-19 <br /> individual sample determined subtracting growth              transgenic parasites, described later. <br /> the PfMSP1-19 test line (Gpf) growth PcMSP1-19                     Plasma antibodies measured ELISA recombinant <br /> control line (Gpc) sample tested (InhPf = Gpc-Gpf). Rabbit         MSP1-19 P. falciparum P. chabaudi 206 <br /> antibodies confirm MSP1-19 specific inhibition raised               baseline samples Mugil cohort. The median OD 206 <br /> against C-terminal fragments P. falciparum P. chabaudi               Mugil children&#226;&#8364;&#8482;s samples PcMSP-19 antigen 21-fold <br /> MSP1-19 earlier study [54].                                           lower PfMSP1-19 antigen (Fig. 1A) majority <br />    Variation assay estimated (+/2) 2 standard                 samples showed little reactivity PcMSP1-19 antigen, <br /> deviations mean Melbourne control sera used            regardless reactivity PfMSP1-19 antigen (Fig. 1B). Of <br /> assays. The level potential PfMSP1-19 specific inhibition            206 samples, 192 (93.2%) positive (defined OD.mean <br /> Melbourne control samples determined subtracting                     +3 standard deviations 9 non-malaria exposed Melbourne <br /> parasite growth PfMSP1-19 line growth                control serum) PfMSP1-19 specific IgG. The prevalence of <br /> PcMSP1-19 line individual sample. Any difference                PfMSP1-19 antibodies associated age, significantly <br /> growth attributed assay variation              greater proportion children older 9 years (97.4%) having <br /> MSP1-19 antibodies detected Melbourne control sera. Two              PfMSP1-19 IgG children 9 years age (87.9%, <br /> standard deviations MSP1-19 specific inhibition Melbourne            P = 0.007). Children greater 9 years significantly <br /> control sera determined separately set experimen-           higher median OD (1.28 [0.65&#226;&#8364;&#8220;1.72]) children 9 years age <br /> tal conditions termed &#226;&#8364;&#732;&#226;&#8364;&#732;variation threshold&#226;&#8364;&#8482;&#226;&#8364;&#8482;. Alterna-          (0.96 [0.17&#226;&#8364;&#8220;1.62], P = 0.006). A significantly higher <br /> tively, number samples arbitrary cutoffs 10%            proportion children concurrent parasitemia time <br /> 15% considered 2 cycle assays using non-dialysed           sampling PfMSP1-19 specific IgG (98.6%) who <br /> dialysed plasma studies [58,59].                  PCR negative (82.1%, P,0.0001), median OD of <br />                                                                             parasitemic children (1.26 [0.57&#226;&#8364;&#8220;1.69]) significantly <br /> Statistical Analysis                                                        higher PCR negative children (0.99 [0.13&#226;&#8364;&#8220;1.46], <br />    Differences categorical variables assessed using             P = 0.01). The associations age infection status and <br /> chi-squared Fisher&#226;&#8364;&#8482;s exact test, appropriate,                  prevalence levels PfMSP1-19 IgG measured ELISA were <br /> differences medians assessed using Mann-Whitney U               largely lower IgG levels children that <br />  <br />  <br />       PLoS ONE | www.plosone.org                                        4                      November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                                    Antibodies Immunity Malaria <br />  <br />  <br />  <br />  <br /> Figure 1. MSP1-19 IgG levels measured ELISA associations age parasitemic status baseline bleed. (A) IgG reactivity <br /> against recombinant PcMSP1-19 PfMSP1-19 206 Mugil plasma samples measured ELISA. (B) Correlation levels PcMSP1-19 <br /> and PfMSP1-19 IgG reactivity measured ELISA individual Mugil plasma. Levels PfMSP1-19 specific IgG (PfMSP1-19 absorbance 405 nm <br /> minus PcMSP1-19 absorbance 405 nm) children ,9 years $9 years age (Median 9.3 years, 41% children ,9 years) baseline bleed <br /> separated based (C) P. falciparum negative (n = 67) (D) P. falciparum positive (n = 139) infection status identified PCR baseline bleed. <br /> For A, C, D, bar box represent median IQR whiskers represent 5th 95th percentiles. <br /> doi:10.1371/journal.pone.0027705.g001 <br />  <br /> were aparasitemic 9 years age baseline bleed              19 specific inhibition samples 4.1% suggesting <br /> (Fig. 1C 1D).                                                              MSP1-19 major target acquired inhibitory <br />                                                                                antibodies. Measurement parasite growth highly repro- <br /> PfMSP1-19 major target growth-inhibitory                           ducible compared duplicate experiments (n = 85, <br /> antibodies                                                                     Table 1, Fig. 3A) samples showing PfMSP1-19 <br />    Plasma samples, dialysis, tested                   specific inhibition (Fig. 3B). <br /> growth inhibition assays conducted 2 cycles parasite                      Samples dialysed remove anti-malarial drugs non- <br /> replication, previously optimized validated                specific malarial inhibitors [67] tested 2 cycle flow- <br /> [67,69]. Final parasitemia measured flow cytometry,                     cytometry based assays (n = 205; sample dialysed due <br /> which greater reproducibility microscopy [67,69].                   limited volume, Fig. 2A). All dialysed plasma samples (n = 205) <br /> Samples 192 206 children tested single            tested duplicate separate assays the <br /> duplicate experiments prior dialysis (Fig. 2A). Results            PcMSP1-19 PfMSP1-19 lines. Comparison the <br /> 14 samples excluded technical reasons.                         median parasite growth duplicate experiments PcPHG <br /> Comparison median growth PcMSP1-19 line                             PfPHG transfected lines indicated little difference the <br /> (expressing C-terminal 19 kDa fragment rodent                     inhibition lines (Fig. 2C); 0.1% growth <br /> malaria P. chabaudi) PfMSP1-19 line (expressing wild-              inhibitory activity classified PfMSP1-19 specific <br /> type C-terminal 19 kDa fragment P. falciparum D10)                (median growth PcMSP1-19 63.8%, PfMSP1-19 63.7%; <br /> samples showed potentially specific inhibition PfMSP1-19                n = 205, P = 0.2, range 222.8% 17.4%). There evidence <br /> line 7.1% (PcMSP1-19 median growth 61.7%, PfMSP1-19                         PfMSP1-19 specific inhibition 10 samples using cut- <br /> median growth 54.6%; n = 192, P,0.0001; range 212.7%                        .10% difference inhibition lines, 2 <br /> 24.9%, Fig. 2B). There evidence PfMSP1-19 specific                      samples using cut-off .15% difference. By comparison, <br /> inhibition (i.e. growth PfMSP1-19 line,growth                    potential PcMSP1-19 specific seen 7 samples using <br /> PcMSP1-19 line) 61 samples using cut-off .10%                    cut-off .10%, sample using cut-off .15% <br /> difference inhibition lines, 20 samples             difference. There high level reproducibility between <br /> using cut-off .15% difference. By comparison, potential                   duplicate experiments (Table 1, Fig. 3C). Total parasite growth <br /> PcMSP1-19 specific inhibition (i.e. growth PcMSP1-19                    inhibition evident proportion dialysed samples; <br /> line,growth PfMSP1-19 line) seen 3 samples                however, inhibitory samples did evidence of <br /> when using cut-off .10% We examined                           PfMSP1-19 specific inhibition (Fig. 3D). When examining the <br /> significance MSP1-19 target inhibitory antibodies                   samples highest level total growth inhibition, <br /> among samples demonstrated highest levels total              median PfMSP1-19 specific inhibition samples was <br /> growth inhibition. When examining samples                1.8%, suggesting MSP1-19 major target of <br /> the highest level total growth inhibition, median PfMSP1-               acquired inhibitory antibodies. <br />  <br />  <br />        PLoS ONE | www.plosone.org                                          5                       November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                                     Antibodies Immunity Malaria <br />  <br />  <br />  <br />  <br /> Figure 2. PfMSP1-19 inhibition Mugil plasma various experimental conditions. (A) Level PfMSP1-19 specific inhibition <br /> measured flow cytometry non-dialysed Mugil plasma (6, n = 192, 2 cycle), dialysed Mugil plasma (+, n = 205, 2 cycle), ammonium sulfate <br /> precipitated PNG plasma 1 10 dilution (&#194;&#164;, n = 6, 2 cycle), ammonium sulfate precipitated PNG plasma 1 5 dilution (w, n = 6, 2 cycle), non- <br /> dialysed Mugil plasma (m, n = 33, 1 cycle) non-dialysed Mugil plasma measured microscopy (N, n = 25, 1 cycle). Central bar (green) represents <br /> the median MSP1-19 specific inhibition plasma samples. Boxes (blue) represent 2 standard deviations mean MSP1-19 specific inhibition <br /> of Melbourne control samples measure assay variability. Bars (red) represent maximum minimum values MSP1-19 specific inhibition <br /> for Melbourne controls. PfMSP1-19 specific inhibition defined growth PcMSP1-19 line minus growth PfMSP1-19 line, expressed a <br /> percentage non-inhibitory controls. Samples tested duplicate correlations duplicate experiments outlined Table 1. <br /> Median growth PcMSP1-19 line PfMSP1-19 line presence (B) non-dialysed Mugil plasma (n = 192) (C) dialysed Mugil plasma <br /> (n = 205) 2 cycle flow cytometry based assays. Error bars represent inter-quartile range dots representing samples inhibition falls <br /> outside range. Horizontal bar box represent median IQR, whiskers represent 5th 95th percentiles. <br /> doi:10.1371/journal.pone.0027705.g002 <br />  <br />   A subset samples (n = 20) high levels MSP1-19                         immunoglobulin removal non-specific inhibitors (Fig. 2A). <br /> antibodies ELISA pooled IgG purified using                         Plasma 5 PNG adults high levels PfMSP1-19 IgG by <br /> ammonium sulfate precipitation, allowing concentration                          ELISA treated ammonium sulfate precipitation purify <br />  <br />  Table 1. Reproducibility parasite growth measurements repeat experiments. <br />  <br />  <br />  Cycle        Method            Plasma              Line           rs     n           P               Line        rs         n         P <br />  <br />  2            F                 ND                  Pc             0.88   85          ,0.0001         Pf          0.8        85        ,0.0001 <br />  2            F                 D                   Pc             0.93   205         ,0.0001         Pf          0.9        204       ,0.0001 <br />  1            F                 ND                  Pc             0.75   25          ,0.0001         Pf          0.76       25        ,0.0001 <br />  1            M                 ND                  Pc             0.71   25          ,0.0001         Pf          0.48       25         = 0.0153 <br />  <br />  F = flow cytometry, M = microscopy. <br />  ND = non-dialysed plasma, D = dialysed plasma. <br />  Pc = P. chabaudi MSP1-19 line; Pf = P. falciparum MSP1-19 line. <br />  rs = spearmans correlation coefficient. <br />  n = number samples compared 2 experiments. <br />  P = significance correlation. <br />  doi:10.1371/journal.pone.0027705.t001 <br />  <br />  <br />  <br />          PLoS ONE | www.plosone.org                                            6                     November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                                      Antibodies Immunity Malaria <br />  <br />  <br />  <br />  <br /> Figure 3. Reproducibility PfMSP1-19 specific growth inhibition assays levels PfMSP1-19 specific inhibition for <br /> representative samples. (A) Correlation PfMSP1-19 line growth duplicate experiments 85 samples non-dialysed Mugil <br /> plasma samples showing high level assay reproducibility (rs = 0.88, n = 85, P,0.0001). (B) Subset non-dialysed Mugil plasma samples showing <br /> total growth inhibitory activity little PfMSP1-19 specific inhibitory activity 2 cycle assays. Confirmation assay able measure <br /> PfMSP1-19 specific inhibition provided use inhibitory rabbit antisera raised PfMSP1-19 (anti-Pf). (C) Correlation PfMSP1- <br /> 19 line growth duplicate experiments dialysed Mugil plasma samples showing high level assay reproducibility (rs = 0.93, n = 204, <br /> P,0.0001). (D) Subset dialysed Mugil plasma showing total growth inhibitory activity little PfMSP1-19 specific inhibitory activity 2 <br /> cycle assays. Correlation parasite growth measured flow cytometry microscopy based 1 cycle assays (E) PcMSP1-19 line <br /> (rs = 0.72, n = 25, P,0.0001) (F) PfMSP1-19 line (rs = 0.59, n = 25, P = 0.0018) highlight comparable levels growth methods. <br /> Parasite growth expressed percentage mean growth panel non-dialysed dialysed Melbourne control sera included each <br /> assay plate. <br /> doi:10.1371/journal.pone.0027705.g003 <br />  <br />  <br /> immunoglobulins. In duplicate experiments, low level                  PcMSP1-19 86.9% PfMSP1-19; n = 6; range 27% to <br /> PfMSP1-19 specific inhibitory activity detected                     13%). The difference growth PcMSP1-19 and <br /> purified IgG 1 10 dilution (median growth 75.2%                 PfMSP1-19 parasite lines ammonium sulfate precipitated <br /> PcMSP1-19 74.6% PfMSP1-19; n = 6; range 24%                          children&#226;&#8364;&#8482;s pooled plasma 0.6% 1 10 dilution 6.2% <br /> 0.7%) using 1 5 dilution (median growth 93.1%                   1 5 dilution. <br />  <br />  <br />        PLoS ONE | www.plosone.org                                           7                        November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                               Antibodies Immunity Malaria <br />  <br />  <br />    These data suggested PfMSP1-19 specific antibodies             PCR). Specific IgG PfMSP1-19 defined reactivity to <br /> not major component vitro growth inhibitory activity         recombinant PfMSP1-19 minus reactivity recombinant <br /> children&#226;&#8364;&#8482;s plasma samples, little specific               PcMSP1-19 sample. There strong evidence a <br /> inhibition observed adult samples tested. Importantly,          protective effect high levels anti-PfMSP1-19 specific <br /> PfMSP1-19 PcMSP1-19 specific rabbit anti-sera tested                 antibodies measured ELISA (IgG reactivity PfMSP1-19 <br /> parallel assays consistently inhibited growth             minus IgG reactivity PcMSP1-19) protection high <br /> respective lines, indicating MSP1-19 specific inhibition         density parasitemia symptomatic P. falciparum infection. High <br /> be effectively measured experiments (Fig. 3B 3D).              levels associated reduced risk high density infection <br />                                                                             (P = 0.0007; Hazard ratio [HR] = 0.40; adjusted HR = 0.48) and <br /> Further evaluation MSP1-19 specific inhibitory                           symptomatic P. falciparum infection (P = 0.0004; HR = 0.35; <br /> antibodies microscopy flow cytometry                                 aHR = 0.43), Fig. 4B, Table 2). There evidence an <br />     To test presence PfMSP1-19 specific inhibitory       association P. chabaudi MSP1-19 specific responses and <br /> antibodies, one-cycle assays performed enable comparison            high density parasitemia symptomatic P. falciparum infection. <br /> with earlier published studies, generally tested inhibition           In comparison antibody associations evaluated this <br /> over cycle only. Similar findings two-cycle assays,       cohort, strength protective association PfMSP1-19- <br /> was little difference median growth                 specific antibodies similar AMA1 (aHR, 0.34), as <br /> PcMSP1-19 PfMSP1-19 parasite lines presence non-              strong antibodies EBA PfRh antigens <br /> dialysed plasma samples (Fig. 2A); results suggest total PfMSP1-19          (Eg. aHR PfRh2_2030 0.2; aHR EBA175 region III&#226;&#8364;&#8220;V <br /> specific inhibition 1.1% (median growth PcMSP1-19                0.27 [21,22]. As reported previously IgG MSP1-19 [43], <br /> 75.2%, PfMSP1-19 74.1%; n = 33, P = 0.9, range 215.1%                antigens [21][22], association between <br /> 11.3%). There high level reproducibility                   low, medium high levels PfMSP1-19 specific IgG time to <br /> experiments (Table 1).                                                      P. falciparum reinfection se (P = 0.81 P = 0.91, light <br />     Since previous studies measured PfMSP1-19                microscopy PCR respectively, Fig. 4A); some <br /> specific inhibitory antibodies used microscopy measure              evidence association high levels PfMSP1-19 IgG <br /> parasite growth, possible use flow cytometry          reduced time moderate density P. falciparum (.500/ml, <br /> the current study explained failure detect growth           P = 0.028). <br /> inhibition effectively. Therefore, 25 plasma samples tested           In order assess association growth inhibitory antibodies <br /> PfMSP1-19 specific inhibitory activity growth measured              protection clinical malaria, MSP1-19 P. falciparum- <br /> by microscopy parallel flow cytometry. Microscopy slides            specific growth inhibition data testing dialysed non- <br /> were blinded person experiments read            dialysed samples used. Although strong association <br /> by authors. Counts 2 separate microscopy                     antibodies PfMSP1-19 measured ELISA and <br /> experiments available 25 samples strong                 protective immunity, evidence PfMSP1-19 <br /> correlation evident repeat experiments (Fig. 2A, Table 1). In           specific inhibitory antibodies associated protection from <br /> these assays little evidence PfMSP1-19 specific growth         malaria. Individuals potentially significant levels PfMSP1- <br /> inhibition (1.3% overall) Mugil samples tested 1 cycle             19 specific inhibition (.10%) using dialysed plasma an <br /> microscopy assay (median growth PcMSP1-19 69.5%                     increased risk symptomatic high density parasitemia <br /> PfMSP1-19 68.2%; n = 25, P = 0.5, range 227.9% 11.6%).                   compared inhibition (Table 2). However, since <br /> There strong correlation measurements PcMSP1-19                little evidence PfMSP1-19 specific growth inhibition <br /> line (rs = 0.72, n = 25, P,0.0001, Fig. 3E) PfMSP1-19 line              samples cohort, evaluating associations between <br /> (rs = 0.59, n = 25, P = 0.0018, Fig. 3F) growth flow                growth inhibition protection malaria problematic. <br /> cytometry microscopy based counts 25 Mugil plasma               There association PfMSP1-19 specific growth inhibition <br /> samples available comparison 1 cycle assays.                         risk symptomatic malaria non-dialysed samples <br />     Taken together, data suggest detection                (Table 2). <br /> PfMSP1-19 specific growth inhibitory activity enhanced <br /> by use one-cycle assays microscopy, confirmed                 Concentration avidity PfMSP1-19 antibodies <br /> findings earlier experiments PfMSP1-19 specific antibodies          estimated ELISA <br /> were major component vitro growth inhibitory                   To assess lack MSP1-19 specific growth <br /> activity children&#226;&#8364;&#8482;s plasma. PfMSP1-19 PcMSP1-19 specific             inhibitory activity attributed low PfMSP1-19 antibody <br /> rabbit anti-sera inhibited growth target lines consistently,         concentration children&#226;&#8364;&#8482;s samples low antibody avidity or <br /> indicating failure detect MSP1-19 specific growth                   affinity, PfMSP1-19 IgG levels avidity compared <br /> inhibitory activity Mugil plasma attributable             growth inhibitory rabbit antisera subset of <br /> problems assay.                                                    children&#226;&#8364;&#8482;s plasma samples; selection plasma samples with <br />                                                                             high reactivity MSP1-19 ELISA used. PfMSP1-19 <br /> Associations acquired antibodies PfMSP1-19                       specific antibody levels growth inhibitory rabbit antisera that <br /> and protection malaria reinfection                                 generated immunization estimated 12.5-fold <br />    To investigate association PfMSP1-19 specific IgG            higher panel highly reactive Mugil plasma <br /> levels ELISA protection malaria infection,                samples (n = 6, Fig. 5A). The rabbit antisera routinely caused <br /> children defined low, medium high responders              70% growth inhibition 1/10 dilution 2-cycle assays <br /> PfMSP1-19 antigen (based tertiles). Levels response              (Fig. 3B), dilution 1/80 resulting loss PfMSP1-19 <br /> then related P. falciparum outcomes: symptomatic P.                 specific growth inhibitory activity (data shown). At 1 80 <br /> falciparum malaria (defined fever plus Pf.5000/ml); high density         dilution, concentration PfMSP1-19 specific IgG rabbit <br /> parasitemia (Pf.5000/ml); moderate density parasitemia (Pf.                 antisera approximately 1.5 fold higher the <br /> 500/ml) reinfection (detected light microscopy              median concentration children&#226;&#8364;&#8482;s plasma samples tested. <br />  <br />  <br />       PLoS ONE | www.plosone.org                                        8                      November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                              Antibodies Immunity Malaria <br />  <br />  <br />  <br />  <br /> Figure 4. PfMSP1-19 specific IgG levels measured ELISA association protection malaria re-infection. (A) Kaplan- <br /> Meier curve showing association PfMSP1-19 specific (PfMSP1-19 minus PcMSP1-19) IgG ELISA time reinfection detected by <br /> PCR low (blue), medium (red) high (green) responders. (B) Kaplan-Meier curve showing association low, medium high levels <br /> of PfMSP1-19 specific IgG risk symptomatic malarial episode (fever+Pf.5000/ml). <br /> doi:10.1371/journal.pone.0027705.g004 <br />  <br />    The avidity PfMSP1-19 specific antibody binding                    falciparum vaccine candidate. Several ELISA based studies have <br /> recombinant PfMSP1-19 estimated using serial dilutions               reported significant associations levels antibodies to <br /> ammonium thiocyanate, added wells allowing                   MSP1-19 protection malaria [38,40&#226;&#8364;&#8220;42,71&#226;&#8364;&#8220;74]; recent <br /> antibodies bind immobilized antigen. The concentration                meta-analysis indicated 19% reduction malaria risk for <br /> ammonium thiocyanate reduced OD 50%, compared                    individuals MSP1-19 antibodies [20]. Functional growth <br /> control (no ammonium thiocyanate added) used measure            inhibitory MSP1-19 specific antibodies reported in <br /> compare avidity samples. The concentration required           samples malaria exposed individuals using vitro assays [54&#226;&#8364;&#8220; <br /> 50% reduction rabbit antisera (4.4 M) comparable             61]. To date, study reported associations PfMSP1- <br /> that observed panel Mugil plasma samples (median 4.7 M,            19 specific growth inhibitory activity protection from <br /> range 3.6 M 5.8 M, n = 6, Fig. 5B). We calculated               symptomatic malaria, quantified importance MSP1-19 <br /> relative reduction antibody binding thiocyanate treatment             target overall growth-inhibitory activity acquired <br /> among samples. At 4.3 M, ammonium thiocyanate reduced <br />                                                                             human antibodies. Here report IgG MSP1-19 <br /> antibody binding children&#226;&#8364;&#8482;s 49.5% (median; range <br />                                                                             measured ELISA associated protection malaria, <br /> 29.8&#226;&#8364;&#8220;82%) 50.5% rabbit antisera (all sera tested 1/ <br />                                                                             MSP1-19 significant target growth-inhibitory antibodies <br /> 2000 dilution). Together, data suggest lack MSP1- <br />                                                                             cohort. <br /> 19 specific growth-inhibitory activity children&#226;&#8364;&#8482;s plasma samples <br /> compared rabbit antisera explained lower                      Of 206 Mugil plasma samples collected baseline, 95.6% <br /> concentration specific antibodies children&#226;&#8364;&#8482;s plasma                PfMSP1-19 IgG positive ELISA, suggesting <br /> samples, lower avidity antibody binding.                      majority children had significant prior exposure P. <br />                                                                             falciparum MSP1-19 antigen, consistent high rate P. <br />                                                                             falciparum reinfections (96% measured PCR) observed the <br /> Discussion <br />                                                                             study [62]. Older children, children PCR positive <br />    MSP1-19 important antigenic region larger 42 kDa            P. falciparum infection baseline, higher <br /> fragment MSP1, long considered promising P.             levels PfMSP1-19 antibodies measured ELISA younger <br />  <br />  <br />       PLoS ONE | www.plosone.org                                        9                      November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                                                 Antibodies Immunity Malaria <br />  <br />  <br />  <br />  Table 2. Cox regression analysis association MSP1-19 responses symptomatic high density parasitemia. <br />  <br />  <br />                                   Fever+Pf.5000 <br />  <br />                                   HR1               [95%CI]                      P                aHR2               [95%CI]                       P <br />  <br />  Pf - Pc ELISA <br />  MSP1-19 (L)3                     1                                                               1 <br />  MSP1-19 (M)                      0.45              0.26          0.78           0.005            0.56               0.31              1.00        0.052 <br />  MSP1-19 (H)                      0.35              0.19          0.64           0.001            0.43               0.23              0.80        0.008 <br />  Pc ELISA <br />  MSP1-19 (L)                      1                                                               1 <br />  MSP1-19 (M)                      1.09              0.48          2.48           0.832            1.14               0.50              2.59        0.762 <br />  MSP1-19 (H)                      0.58              0.23          1.50           0.262            0.64               0.25              1.66        0.358 <br />  GIA dialysed <br />  MSP1-19 (0%)4                    1                                                               1 <br />  MSP1-19 (,5%)                    1.85              0.98          3.52           0.059            1.72               0.90              3.29        0.104 <br />  MSP1-19 (5&#226;&#8364;&#8220;9.9%)                 2.68              1.37          5.24           0.004            2.71               1.33              5.52        0.006 <br />  MSP1-19 (.10%)                   10.41             4.36          24.84          ,0.001           8.20               3.34              20.11       ,0.001 <br />  GIA non-dialysed <br />  MSP1-19 (0%)                     1                                                               1 <br />  MSP1-19 (,5%)                    0.67              0.16          2.81           0.584            0.89               0.21              3.77        0.869 <br />  MSP1-19 (5&#226;&#8364;&#8220;9.9%)                 0.88              0.23          3.32           0.852            1.03               0.27              3.96        0.967 <br />  MSP1-19 (.10%)                   1.66              0.48          5.79           0.424            1.90               0.53              6.81        0.323 <br />  <br />  1 <br />   HR &#226;&#8364;&#8220; hazard ratio risk malaria (fever+P. falciparum parasitemia .5000 parasites microlitre blood). <br />  2 <br />   aHR &#226;&#8364;&#8220; adjusted hazard ratios (adjusted age location residence). <br />  3 <br />   High (H), medium (M), low (L) antibody levels defined tertiles. <br />  4 <br />   Level MSP1-19 specific inhibition indicated brackets. <br />  doi:10.1371/journal.pone.0027705.t002 <br />  <br />  <br /> children children PCR negative. These data suggest                         (PfMSP1-19 OD minus PcMSP1-19 OD) antibodies associ- <br /> that levels PfMSP1-19 specific antibodies measured ELISA                           ated reduced risk symptomatic malaria, remained <br /> are associated recent cumulative exposure P. falciparum                      significant adjusting differences age location of <br /> as expected.                                                                             residence. Time moderate high density P. falciparum <br />    Analysis association PfMSP1-19 antibody levels                         infection significantly increased children high PfMSP1- <br /> measured ELISA P. falciparum malaria episode post                           19 antibody levels, consistent current <br /> drug treatment indicated high levels PfMSP1-19 specific                          understanding acquired immunity proposed mechanisms <br />  <br />  <br />  <br />  <br /> Figure 5. PfMSP1-19 antibody concentration avidity binding Mugil plasma rabbit sera. (A) Comparison PfMSP1-19 <br /> specific antibody levels estimated ELISA Mugil plasma growth inhibitory vaccinated rabbit sera raised PfMSP1-19 (anti-Pf). <br /> Relative levels expressed proportion PfMSP1-19 rabbit antisera. (B) Comparison IC50 (M) ammonium thiocyanate inhibition of <br /> PfMSP1-19 antibody binding recombinant PfMSP1-19 Mugil plasma growth inhibitory vaccinated rabbit sera raised PfMSP1-19. The <br /> 6 Mugil plasma samples tested selected based having high levels PfMSP1-19 IgG measured ELISA. Bars represent mean and <br /> range 2 independent experiments (antibody concentration Figure A) mean standard deviation independent experiments <br /> (thiocyanate concentration Figure B). <br /> doi:10.1371/journal.pone.0027705.g005 <br />  <br />  <br />        PLoS ONE | www.plosone.org                                                 10                          November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                                   Antibodies Immunity Malaria <br />  <br />  <br /> of action anti-MSP1-19 antibodies. These findings similar              inhibition appear likely negative PfMSP1-19 specific <br /> to previous study MSP1-19 antibodies cohort [43].                 inhibition reflects assay variability PcMSP1-19-like <br /> However, study assessed IgG specificity PfMSP1-19                inhibitor. It interesting note maximum minimum <br /> by deducting reactivity recombinant MSP1-19 P. chabaudi               levels notional MSP1-19 specific inhibition Melbourne <br /> order account non-specific binding, concern             control samples lie similar levels maximum minimum <br /> is expressed researchers field.                                levels inhibition seen Mugil samples. Again suggests <br />     The results study support findings number              MSP1-19 specific inhibition detected Mugil samples could <br /> other studies shown association IgG                      explained assay variability. Importantly, variability seen <br /> antibody levels PfMSP1-19 measured ELISA control                  Melbourne control samples indication poor <br /> parasitemia protection symptomatic P. falciparum malaria               reproducibility flow cytometry based assays, a <br /> [38,40&#226;&#8364;&#8220;42,71&#226;&#8364;&#8220;74]. The association MSP1-19 antibody                     high level reproducibility measurements parasite growth <br /> levels protection disease evident infants              duplicate wells experiments this <br /> young children, suggests protection associated                 study. <br /> MSP1-19 antibodies develops early people&#226;&#8364;&#8482;s exposure                         One possible explanation lack PfMSP1-19 specific <br /> malaria [38,40,74]. Combined, studies suggest IgG                   growth inhibition seen study related level of <br /> antibodies MSP1-19 important component                         exposure cohort compared others. Previous studies <br /> immunity P. falciparum malaria alternatively act                reported high levels PfMSP1-19 specific inhibition samples <br /> strong predictive marker exposure, immunity.                      collected children adults living highly malaria <br />     Our comprehensive testing suggests little PfMSP1-            endemic areas [54,61] correlation age and <br /> 19 specific growth inhibition plasma samples Mugil                 PfMSP1-19 specific growth inhibition identified the <br /> cohort, various experimental conditions. Furthermore,                studies [61]. Other studies reported PfMSP1-19 specific <br /> potential MSP1-19 specific inhibitory activity associated              growth inhibitory activity samples collected people with <br /> with protection malaria re-infection. The median level              limited exposure P. falciparum malaria [55,56]. Therefore, these <br /> PfMSP1-19 specific inhibition non-dialysed Mugil plasma                    studies suggest previously detected PfMSP1-19 growth <br /> tested 2 cycle assay, dialysed Mugil plasma tested 2 cycle           inhibitory antibodies confined samples collected from <br /> assay, non-dialysed Mugil plasma 1 cycle assay measured                areas high endemicity people high levels of <br /> flow cytometry microscopy, ammonium sulfate precipitated                exposure. The levels growth inhibitory activity PfMSP1-19 <br /> IgG 1 10 1 5 dilution generally minimal lower            specific antibodies plasma samples acute phase of <br /> than levels reported studies [54&#226;&#8364;&#8220;58]. The highest                 reinfection examined study; antibodies were <br /> median PfMSP1-19 specific inhibition recorded 2 cycle                 measured enrolment. It likely total antibody levels to <br /> assays using non-dialysed samples. However,                PfMSP1-19 rise response reinfection. However, the <br /> samples PfMSP1-19 specific inhibition commonly                    minimal levels PfMSP1-19 specific growth inhibitory activity <br /> used cut-off 15% samples levels PfMSP1-19                     seen study population, lack association <br /> specific inhibition approaching highest levels seen               MSP1-19 specific inhibitory antibodies active <br /> studies, despite fact cycle growth inhibition assays              parasitemia enrolment, suggests subsequent parasite <br /> have previously reported greater sensitivity compared             reinfection unlikely increase PfMSP1-19 inhibitory activity. <br /> to 1 cycle assays [67,69,75]. This suggests PfMSP1-19                    Estimation PfMSP-19 IgG concentration rabbit antisera <br /> specific inhibition seen cycle non-dialysed samples                Mugil plasma high levels PfMSP1-19 antibodies <br /> might attributable assay variation antibody-                 suggested antibody concentration important factor <br /> mediated growth inhibition. Other antigens identified                limiting ability detect PfMSP1-19 specific inhibition using this <br /> or proposed targets acquired human growth inhibitory                     assay. PfMSP1-19 specific IgG 12.5 fold higher rabbit <br /> antibodies, including AMA1 [76], erythrocyte binding antigens                  antisera panel Mugil plasma. When rabbit antisera <br /> [66], PfRh ligands [66]. These important targets                 diluted concentration IgG similar <br /> inhibitory antibodies population.                                      seen Mugil plasma, loss growth <br />     Importantly, rabbit polyclonal antibodies raised recom-            inhibitory activity. This suggests levels PfMSP1-19 <br /> binant PfMSP1-19 PcMSP1-19 used assays                     antibodies Mugil samples high allow <br /> consistently specifically inhibited growth target              detection MSP1-19 specific growth inhibition assay. The <br /> parasite lines. This suggests antibody mediated MSP1-19                   avidity PfMSP1-19 specific binding recombinant <br /> specific inhibition malaria exposed samples measured               PfMSP1-19 antigen appeared comparable rabbit antisera and <br /> if inhibitory activity antibodies high enough. In          Mugil plasma, suggesting differences antibody avidity or <br /> study, variability threshold determined paired                      affinity did contribute reduced PfMSP1-19 specific <br /> (PcMSP1-19 line PfMSP1-19 line) Melbourne control samples                   inhibition Mugil plasma compared rabbit antisera. However, <br /> to provide reliable indicator measured MSP1-                results interpreted caution using <br /> 19 specific inhibition attributable assay variability.        ammonium thiocyanate elution ELISA provides estimate of <br /> In way hoped establish valid cut-off                 relative avidity antibodies vitro, faithfully <br /> defining MSP1-19 positivity negativity using arbitrary              represent avidity affinity vivo. Additionally, differences the <br /> value 5 15% adopted previously [58&#226;&#8364;&#8220;60]. Using                fine specificity antibodies contribute differences <br /> this method, notional MSP1-19 specific inhibition detected              observed inhibitory activity human rabbit antibodies. <br /> majority samples explained assay variability.                      The limited PfMSP1-19 growth inhibitory activity detected in <br />     It noticeable number samples displaying                    study differs markedly earlier published studies reporting <br /> PfMSP1-19 specific inhibition usually balanced number               greater levels MSP1-19 specific inhibition serum plasma <br /> of samples showing negative PfMSP1-19 specific inhibition (i.e.                (Table S1) [54,55,61]. One possible explanation noted by <br /> PcMSP1-19 specific inhibition), exception cycle              Murhandarwati et al. (2009) [59], earlier studies <br /> non-dialysed data. Given distribution MSP1-19 specific                  used pyrimethamine sensitive D10 wildtype line test line <br />  <br />  <br />        PLoS ONE | www.plosone.org                                         11                       November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                                                         Antibodies Immunity Malaria <br />  <br />  <br />                                                                                                   b <br /> compared pyrimethamine resistant PcMEGF line                                                M = microscopy based assay. F = flow cytometry based assay. <br /> [54,55,61]. In recent studies [56&#226;&#8364;&#8220;60],                                        H = Hypoxanthine uptake assay. <br /> pyrimethamine resistant PfM39 (also PfPHG line study)                                   c <br />                                                                                                    Microscopy based assays Bagabag Island Madang <br /> PfMSP1-19 transfected line used PcMEGF                                     samples completed using D10 wildtype line. Hypo- <br /> or PyMEGF (also PcPHG line study) comparison line,                                      xanthine uptake based assays Bagabag Island Madang <br /> ensuring residual pyrimethamine plasma samples                                       samples completed using transfected D10-PfM39 line <br /> should contribute differential growth lines.                                  [54]. <br /> More recent studies [59,60], including study, moved                               d <br /> towards using flow cytometry based counts parasitemia                                     Interpretation Figures 2C 2D information in <br /> has reduced variability improved reproducibility compared                                 text. <br />                                                                                                  d <br /> microscopy based measurements [67,69,75]. It possible                                      Inhibition minimum 6 months (16% n = 24) maximum at <br /> microscopy-based assays able measure growth differences                                   24&#226;&#8364;&#8220;30 months (29%, n = 19). <br />                                                                                                  e <br /> between Pf Pc lines detected flow                                          Inhibition range 9 20 returned travelers considered to <br /> cytometry, comparison assays suggested                                   significant PfMSP1-19 specific inhibition. Data for <br /> that similar results.                                                                  remaining 11 travelers reported. <br />    In conclusion, MSP1-19 IgG levels measured                                        f <br />                                                                                                    Interpretation Figures 2B 3. Spaghetti plots of <br /> ELISA associated protection, little                                    timepoints samples available supplementary file 4 of <br /> PfMSP1-19 specific growth inhibitory activity measurable                                  manuscript. <br /> Mugil cohort, probably antibodies high                                     g <br /> enough concentration. This suggests association                                   Calculated median 137 samples listed table 1 the <br /> MSP1-19 IgG levels measured ELISA protection                                         manuscript. Calculated medians 3 timepoints t = 0 <br /> disease marker protective immunity                                 (9%, n = 65), t = 1 (10%, n = 37), t = 28 (214%, n = 35). <br /> directly involved protective mechanisms, indicate                                 NR = reported manuscript. <br /> MSP1-19 antibodies contribute protection mechanisms                                (DOCX) <br /> than growth inhibition. Studies humanized mouse model <br /> suggest antibodies MSP1-19 protect parasit- <br /> emia interaction dependent Fc Receptors                                      Acknowledgments <br /> phagocytic cells, inhibition invasion [52]. In                                  Thanks participants study, staff PNG IMR technical <br /> conclusion, findings presented contribute                                      assistance, Jack Richards Joanne Chesson help sample <br /> understanding human immunity malaria, particularly                                   processing advice, Arlene Dent Jim Kazura helpful <br /> targets mechanisms immunity, valuable                                   discussions. <br /> informing vaccine development MSP1 antigens. <br />                                                                                                Author Contributions <br /> Supporting Information                                                                         Conceived designed experiments: DW JB BC IM. Performed the <br />                                                                                                experiments: DW. Analyzed data: DW JB FF IM BC SE PG. <br /> Table S1 Summary PfMSP1-19 specific inhibition levels <br />                                                                                                Contributed reagents/materials/analysis tools: IM PG LT PM PS ED FF. <br /> reported different studies.                                                                 Wrote paper: DW JB SE BC IM FF. Co-ordinated clinical studies: IM <br />                                                                                              PM ED LT PS. <br />       S = serum. P = plasma. <br />  <br />  <br /> References <br /> 1. Elliott SR, Beeson JG (2008) Estimating burden global mortality                   10. Migot-Nabias F, Luty AJ, Ringwald P, Vaillant M, Dubois B, et al. (1999) <br />    children aged ,5 years pathogen-specific causes. Clin Infect Dis 46:                         Immune responses Plasmodium falciparum asexual blood-stage antigens and <br />    1794&#226;&#8364;&#8220;1795.                                                                                      disease susceptibility Gabonese Cameroonian children. Am J Trop Med <br /> 2. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, et al. (2008) The                           Hyg 61: 488&#226;&#8364;&#8220;494. <br />    limits intensity Plasmodium falciparum transmission: implications malaria        11. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, et al. (2000) Cytophilic <br />    control elimination worldwide. PLoS Med 5: e38.                                             immunoglobulin responses Plasmodium falciparum glutamate-rich protein are <br /> 3. Rowe AK, Rowe SY, Snow RW, Korenromp EL, Schellenberg JR, et al. (2006)                         correlated protection clinical malaria Dielmo, Senegal. Infect <br />    The burden malaria mortality African children year 2000.                        Immun 68: 2617&#226;&#8364;&#8220;2620. <br />    Int J Epidemiol 35: 691&#226;&#8364;&#8220;704.                                                                12. Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, et al. <br /> 4. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution                    (2003) Serum IgG3 Plasmodium falciparum merozoite surface protein 2 is <br />    clinical episodes Plasmodium falciparum malaria. Nature 434: 214&#226;&#8364;&#8220;217.                     strongly associated reduced prospective risk malaria. Parasite Immunol <br /> 5. Gaur D, Mayer DC, Miller LH (2004) Parasite ligand-host receptor interactions                   25: 307&#226;&#8364;&#8220;312. <br />    invasion erythrocytes Plasmodium merozoites. Int J Parasitol 34:               13. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P (2004) Association between <br />    1413&#226;&#8364;&#8220;1429.                                                                                      protection clinical malaria antibodies merozoite surface antigens <br /> 6. Marsh K, Kinyanjui S (2006) Immune effector mechanisms malaria. Parasite                     area hyperendemicity Myanmar: complementarity responses <br />    Immunol 28: 51&#226;&#8364;&#8220;60.                                                                              merozoite surface protein 3 220-kilodalton glutamate-rich protein. <br /> 7. al-Yaman F, Genton B, Anders R, Taraika J, Ginny M, et al. (1995) Assessment                    Infect Immun 72: 247&#226;&#8364;&#8220;252. <br />    role humoral response Plasmodium falciparum MSP2 compared               14. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, et al. (2004) Human <br />    RESA SPf66 protecting Papua New Guinean children clinical                           antibodies recombinant protein constructs Plasmodium falciparum Apical <br />    malaria. Parasite Immunol 17: 493&#226;&#8364;&#8220;501.                                                          Membrane Antigen 1 (AMA1) associations protection from <br /> 8. Taylor RR, Allen SJ, Greenwood BM, Riley EM (1998) IgG3 antibodies                           malaria. Vaccine 23: 718&#226;&#8364;&#8220;728. <br />    Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence             15. Polley SD, Tetteh KK, Lloyd JM, Akpogheneta OJ, Greenwood BM, et al. <br />    age association clinical immunity malaria. Am J Trop Med Hyg                   (2007) Plasmodium falciparum merozoite surface protein 3 target allele- <br />    58: 406&#226;&#8364;&#8220;413.                                                                                    specific immunity alleles maintained natural selection. J Infect Dis <br /> 9. Alifrangis M, Lemnge MM, Moon R, Theisen M, Bygbjerg I, et al. (1999) IgG                       195: 279&#226;&#8364;&#8220;287. <br />    reactivities recombinant Rhoptry-Associated Protein-1 (rRAP-1)                  16. Osier FH, Polley SD, Mwangi T, Lowe B, Conway DJ, et al. (2007) Naturally <br />    associated mixed Plasmodium infections protection disease                   acquired antibodies polymorphic conserved epitopes Plasmodium <br />    Tanzanian children. Parasitology 119(Pt 4): 337&#226;&#8364;&#8220;342.                                            falciparum merozoite surface protein 3. Parasite Immunol 29: 387&#226;&#8364;&#8220;394. <br />  <br />  <br />  <br />  <br />         PLoS ONE | www.plosone.org                                                        12                           November 2011 | Volume 6 | Issue 11 | e27705 <br />                                                                                                                                           Antibodies Immunity Malaria <br />  <br />  <br /> 17. Roussilhon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, et al. (2007) Long-               42. Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, et al. (2005) Antibodies to <br />     term clinical protection falciparum malaria strongly associated IgG3               conserved C-terminal domain Plasmodium falciparum merozoite surface <br />     antibodies merozoite surface protein 3. PLoS Med 4: e320.                                    protein 1 merozoite extract relationship vitro <br /> 18. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, et al. (2008) Breadth                     inhibitory antibodies protection clinical malaria Senegalese <br />     magnitude antibody responses multiple Plasmodium falciparum merozoite antigens            village. J Infect Dis 191: 264&#226;&#8364;&#8220;271. <br />     associated protection clinical malaria. Infect Immun 76: 2240&#226;&#8364;&#8220;2248.           43. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, et al. (2009) <br /> 19. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, et al. (2008)                           Immunoglobulin G subclass-specific responses Plasmodium falciparum <br />     Humoral responses Plasmodium falciparum blood-stage antigens association                 merozoite antigens associated control parasitemia protection <br />     incidence clinical malaria children living area seasonal malaria            symptomatic illness. Infect Immun 77: 1165&#226;&#8364;&#8220;1174. <br />     transmission Burkina Faso, West Africa. Infect Immun 76: 759&#226;&#8364;&#8220;766.                        44. Egan AF, Burghaus P, Druilhe P, Holder AA, Riley EM (1999) Human <br /> 20. Fowkes FJ, Richards JS, Simpson JA, Beeson JG (2010) The relationship                           antibodies 19 kDa C-terminal fragment Plasmodium falciparum merozoite <br />     anti-merozoite antibodies incidence Plasmodium falciparum                        surface protein 1 inhibit parasite growth vitro. Parasite Immunol 21: 133&#226;&#8364;&#8220;139. <br />     malaria: A systematic review meta-analysis. PLoS Med 7: e1000218.                       45. Chappel JA, Egan AF, Riley EM, Druilhe P, Holder AA (1994) Naturally <br /> 21. Reiling L, Richards JS, Fowkes FJ, Barry AE, Triglia T, et al. (2010) Evidence                  acquired human antibodies recognize epidermal growth factor- <br />     erythrocyte invasion ligand PfRh2 target protective immunity                   like module Plasmodium falciparum merozoite surface protein 1 not <br />     Plasmodium falciparum malaria. J Immunol 185: 6157&#226;&#8364;&#8220;6167.                                inhibit parasite growth vitro. Infect Immun 62: 4488&#226;&#8364;&#8220;4494. <br /> 22. Richards JS, Stanisic DI, Fowkes FJ, Tavul L, Dabod E, et al. (2010) Association            46. Daly TM, Long CA (1995) Humoral response carboxyl-terminal region of <br />     naturally acquired antibodies erythrocyte-binding antigens                        merozoite surface protein-1 plays predominant role controlling blood- <br />     Plasmodium falciparum protection malaria high-density parasitemia.                 stage infection rodent malaria. J Immunol 155: 236&#226;&#8364;&#8220;243. <br />     Clin Infect Dis 51: e50&#226;&#8364;&#8220;60.                                                                 47. Hirunpetcharat C, Tian JH, Kaslow DC, van Rooijen N, Kumar S, et al. (1997) <br /> 23. Beeson JG, Osier FH, Engwerda CR (2008) Recent insights humoral                        Complete protective immunity induced mice immunization 19- <br />     cellular immune responses malaria. Trends Parasitol 24: 578&#226;&#8364;&#8220;584.                        kilodalton carboxyl-terminal fragment merozoite surface protein-1 <br /> 24. Richards JS, Beeson JG (2009) The future blood-stage vaccines                       (MSP1[19]) Plasmodium yoelli expressed Saccharomyces cerevisiae: <br />     malaria. Immunol Cell Biol 87: 377&#226;&#8364;&#8220;390.                                                         correlation protection antigen-specific antibody titer, with <br /> 25. Tanabe K, Mackay M, Goman M, Scaife JG (1987) Allelic dimorphism                           effector CD4+ T cells. J Immunol 159: 3400&#226;&#8364;&#8220;3411. <br />     surface antigen gene malaria parasite Plasmodium falciparum. J Mol Biol 195:         48. Ahlborg N, Ling IT, Howard W, Holder AA, Riley EM (2002) Protective <br />     273&#226;&#8364;&#8220;287.                                                                                        immune responses 42-kilodalton (kDa) region Plasmodium yoelli <br /> 26. Miller LH, Roberts T, Shahabuddin M, McCutchan TF (1993) Analysis                            merozoite surface protein 1 induced C-terminal 19-kDa region but <br />     sequence diversity Plasmodium falciparum merozoite surface protein-1 (MSP-               adjacent 33-kDa region. Infect Immun 70: 820&#226;&#8364;&#8220;825. <br />     1). Mol Biochem Parasitol 59: 1&#226;&#8364;&#8220;14.                                                         49. Wipasa J, Xu H, Makobongo M, Gatton M, Stowers A, et al. (2002) Nature and <br /> 27. O&#226;&#8364;&#8482;Donnell RA, Saul A, Cowman AF, Crabb BS (2000) Functional conservation                        specificity required protective immune response develops post- <br />     malaria vaccine antigen MSP-119across distantly related Plasmodium                       challenge mice vaccinated 19-kilodalton fragment Plasmodium yoelli <br />     species. Nat Med 6: 91&#226;&#8364;&#8220;95.                                                                      merozoite surface protein 1. Infect Immun 70: 6013&#226;&#8364;&#8220;6020. <br /> 28. Sanders PR, Kats LM, Drew DR, O&#226;&#8364;&#8482;Donnell RA, O&#226;&#8364;&#8482;Neill M, et al. (2006) A set                  50. Singh S, Miura K, Zhou H, Muratova O, Keegan B, et al. (2006) Immunity to <br />     glycosylphosphatidyl inositol-anchored membrane proteins Plasmodium                       recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): <br />     falciparum refractory genetic deletion. Infect Immun 74: 4330&#226;&#8364;&#8220;4338.                       protection Aotus nancymai monkeys strongly correlates anti-MSP1 <br /> 29. Lyon JA, Geller RH, Haynes JD, Chulay JD, Weber JL (1986) Epitope map                       antibody titer vitro parasite-inhibitory activity. Infect Immun 74: <br />     processing scheme 195,000-dalton surface glycoprotein Plasmodium                     4573&#226;&#8364;&#8220;4580. <br />     falciparum merozoites deduced cloned overlapping segments gene. <br />                                                                                                 51. Nwuba RI, Sodeinde O, Anumudu CI, Omosun YO, Odaibo AB, et al. (2002) <br />     Proc Natl Acad Sci U S A 83: 2989&#226;&#8364;&#8220;2993. <br />                                                                                                     The human immune response Plasmodium falciparum includes antibodies <br /> 30. McBride JS, Heidrich HG (1987) Fragments polymorphic Mr 185,000 <br />                                                                                                     inhibit merozoite surface protein 1 secondary processing blocking <br />     glycoprotein surface isolated Plasmodium falciparum merozoites form <br />                                                                                                     antibodies. Infect Immun 70: 5328&#226;&#8364;&#8220;5331. <br />     antigenic complex. Mol Biochem Parasitol 23: 71&#226;&#8364;&#8220;84. <br />                                                                                                 52. McIntosh RS, Shi J, Jennings RM, Chappel JC, Koning-Ward TF, et al. <br /> 31. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA (1990) A <br />                                                                                                     (2007) The importance human FcgammaRI mediating protection to <br />     single fragment malaria merozoite surface protein remains parasite <br />                                                                                                     malaria. PLoS Pathog 3: e72. <br />     red cell invasion target invasion-inhibiting antibodies. J Exp <br />                                                                                                 53. Gilson PR, O&#226;&#8364;&#8482;Donnell RA, Nebl T, Sanders PR, Wickham ME, et al. (2008) <br />     Med 172: 379&#226;&#8364;&#8220;382. <br />                                                                                                     MSP1(19) miniproteins serve targets invasion inhibitory antibodies in <br /> 32. Blackman MJ, Ling IT, Nicholls SC, Holder AA (1991) Proteolytic processing of <br />                                                                                                     Plasmodium falciparum provided contain correct domains cell surface <br />     Plasmodium falciparum merozoite surface protein-1 produces membrane- <br />     bound fragment containing epidermal growth factor-like domains. Mol                         trafficking. Mol Microbiol 68: 124&#226;&#8364;&#8220;138. <br />     Biochem Parasitol 49: 29&#226;&#8364;&#8220;33.                                                                54. O&#226;&#8364;&#8482;Donnell RA, Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, et al. <br /> 33. Blackman MJ, Holder AA (1992) Secondary processing Plasmodium                            (2001) Antibodies merozoite surface protein (MSP)-1(19) major <br />     falciparum merozoite surface protein-1 (MSP1) calcium-dependent                            component invasion-inhibitory response individuals immune to <br />     membrane-bound serine protease: shedding MSP133 noncovalently                           malaria. J Exp Med 193: 1403&#226;&#8364;&#8220;1412. <br />     associated complex fragments MSP1. Mol Biochem Parasitol                  55. John CC, O&#226;&#8364;&#8482;Donnell RA, Sumba PO, Moormann AM, Koning-Ward TF, <br />     50: 307&#226;&#8364;&#8220;315.                                                                                    et al. (2004) Evidence invasion-inhibitory antibodies specific 19-kDa <br /> 34. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA (1994) Antibodies inhibit                     fragment merozoite surface protein-1 (MSP-1 19) play protective role <br />     protease-mediated processing malaria merozoite surface protein. J Exp                  blood-stage Plasmodium falciparum infection individuals malaria <br />     Med 180: 389&#226;&#8364;&#8220;393.                                                                               endemic area Africa. J Immunol 173: 666&#226;&#8364;&#8220;672. <br /> 35. Boyle MJ, Wilson DW, Richards JS, Riglar DT, Tetteh KK, et al. (2010)                       56. Dent A, Malhotra I, Mungai P, M <br /> </body></html>